Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 32Cisplatin 31durvalumab 15pembrolizumab 14Fluorouracil 13Oxaliplatin 12Leucovorin 12Capecitabine 10Bevacizumab 8lenvatinib 7Nivolumab 7zanidatamab 4Trastuzumab 4S 1 (combination) 4Paclitaxel 4Liquid Biopsy 4Irinotecan 4Carboplatin 4Albumin-Bound Paclitaxel 4tremelimumab 3tislelizumab 3irinotecan sucrosofate 3Injections 3Folfox protocol 3130-nm albumin-bound paclitaxel 3toripalimab 2pertuzumab 2niraparib 2ivosidenib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Circulating Tumor DNA × 1 year × Clear all
NCT07142226 2026-03-18

Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC

CHA University

Recruiting
200 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡